Compositions of glycopyrronium salt for inhalation

US10314784B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Barbara Haeberlin · Riehen, CH
• Frank Stowasser
• Wolfgang Wirth · Bensberg, DE
• Anton Baumberger · Binningen, CH
• Stephan Abel · Weil, DE
• Sebastian Kaerger · Riehen, CH
• Thomas Kieckbusch · Lörrach, DE

Key dates

• Filing date: Dec 7, 2015
• Grant date: Jun 11, 2019
• Expiry date: Oct 10, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.